This article was originally published in The Tan Sheet
McKesson's BioServices division has inked a five-year, $2.8 mil. contract with NCCAM to develop research-grade cranberry products for center-funded basic, clinical research on role of cranberry "in the prevention and treatment of urinary tract infections" and other applications, firm says Oct. 23. McKesson will subcontract with Ocean Spray, which will donate "research product and analytical research services." Test batches and prototypes are being developed now for a cranberry capsule, placebo capsule, standardized juice cocktail similar to firm's flagship beverage and placebo beverage that replicates cocktail flavor without cranberry. McKesson's responsibilities will include labeling, storage, distribution and delivery of products. Actual product for use in research expected in Fall 2003...
You may also be interested in...
NIH plans to commit up to $2.6 mil. in fiscal year 2004 for Phase I and II trials on cranberry and its constituents' role in the treatment and prevention of urinary tract infections and other conditions
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.